CalciMedica, Inc. (NASDAQ:CALC) Short Interest Up 35.0% in February

CalciMedica, Inc. (NASDAQ:CALC) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 93,300 shares, a growth of 35.0% from the January 31st total of 69,100 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average daily trading volume, of 40,600 shares, the short-interest ratio is presently 2.3 days.

Hedge Funds Weigh In On CalciMedica

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in CalciMedica by 51.2% in the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after purchasing an additional 22,525 shares in the last quarter. Atria Investments Inc boosted its holdings in shares of CalciMedica by 136.5% in the third quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock valued at $117,000 after acquiring an additional 15,296 shares during the period. PVG Asset Management Corp acquired a new stake in shares of CalciMedica in the third quarter valued at approximately $67,000. Millennium Management LLC boosted its holdings in shares of CalciMedica by 30.5% in the fourth quarter. Millennium Management LLC now owns 72,057 shares of the company’s stock valued at $255,000 after acquiring an additional 16,824 shares during the period. Finally, Cetera Investment Advisers boosted its holdings in shares of CalciMedica by 37.1% in the fourth quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock valued at $60,000 after acquiring an additional 4,566 shares during the period.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of CalciMedica in a research note on Thursday, November 14th.

CalciMedica Stock Down 0.9 %

Shares of CALC opened at $2.20 on Tuesday. The stock has a 50 day moving average price of $2.78 and a 200 day moving average price of $3.46. The company has a market capitalization of $29.66 million, a price-to-earnings ratio of -2.04 and a beta of 1.18. CalciMedica has a 52-week low of $1.91 and a 52-week high of $6.27.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.